Medical treatments in the short term management of reflux oesophagitis (Q24245220)

3

0 references

Cathy Preston

4

author given names

Cathryn

author last names

Preston

1 reference

29 October 2023

Clare Donnellan

5

author given names

Clare

author last names

Donnellan

1 reference

29 October 2023

Mostafizur Khan

author given names

Mostafizur

author last names

Khan

Cochrane Database of Systematic Reviews

1

1 reference

29 October 2023

language of work or name

1 reference

18 April 2007

0 references

published in

0 references

cites work

Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Reflux esophagitis therapy: sucralfate versus ranitidine in a double blind multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Sucralfate versus placebo in reflux esophagitis. A double-blind multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Double blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Combined therapy with cisapride and cimetidine in severe reflux oesophagitis: a double blind controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Heartburn treatment in primary care: randomised, double blind study for 8 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Evidence for therapeutic equivalence of lansoprazole 30mg and esomeprazole 40mg in the treatment of erosive oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Comparison of pantoprazole 20 mg to ranitidine 150 mg b.i.d. in the treatment of mild gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Randomized comparative study of omeprazole and famotidine in reflux esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Comparable efficacy of pantoprazole and omeprazole in patients with moderate to severe reflux esophagitis. Results of a multinational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Efficacy and tolerability of pantoprazole versus ranitidine in the treatment of reflux esophagitis and the influence of Helicobacter pylori infection on healing rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Assessment of effectiveness of different dosage regimens of pantoprazole in controlling symptoms and healing esophageal lesions of patients with mild erosive esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Healing of erosive esophagitis with sucralfate and cimetidine: influence of pretreatment lower esophageal sphincter pressure and serum pepsinogen I levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Once-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Efficacy of twice daily doses of 40 or 20 milligrams famotidine or 150 milligrams ranitidine for treatment of patients with moderate to severe erosive esophagitis. Famotidine Erosive Esophagitis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

No clinical benefit of adding cisapride to pantoprazole for treatment of gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Relapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

The effect of cisapride on oesophageal motility and lower sphincter function in patients with gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

The basis for the decreased response to proton pump inhibitors in gastro‐oesophageal reflux disease patients without erosive oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Ranitidine and high-dose antacid in reflux oesophagitis. A randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Rabeprazole improves health-related quality of life in patients with erosive gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Symptom-relieving Effect of Esomeprazole 40 mg Daily in Patients with Heartburn

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Esomeprazole provides improved acid control vs. omeprazole In patients with symptoms of gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Short- and long-term therapy for reflux oesophagitis in the elderly: a multi-centre, placebo-controlled study with pantoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Effect of cimetidine in symptomatic gastro-oesophageal reflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Treatment advances in acid secretory disorders: the promise of rapid symptom relief with disease resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Trends in the management of gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

The impact of gastroesophageal reflux disease on health-related quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Clinical Manifestations and Esophageal Complications of GERD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Ranitidine in reflux oesophagitis. A double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

Comparison of the effect of sucralfate and ranitidine in reflux esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Sucralfate versus alginate/antacid in the treatment of peptic esophagitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Multicenter trial of sucralfate suspension for the treatment of reflux esophagitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Combination therapy of sucralfate and cimetidine, compared with sucralfate monotherapy, in patients with peptic reflux esophagitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Healing and relapse of severe peptic esophagitis after treatment with omeprazole

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Omeprazole versus ranitidine in erosive oesophagitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Ranitidine versus cimetidine in the healing of erosive esophagitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Comparison of two dosing regimens of cisapride in the treatment of reflux oesophagitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Treatment of reflux oesophagitis of moderate and severe grade with ranitidine or pantoprazole--comparison of 24-hour intragastric and oesophageal pH

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

[Different healing tendencies of reflux esophagitis following omeprazole and ranitidine. Results of a German-Austrian-Swiss multicenter study]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Histamine H2 antagonists in acute upper gastrointestinal hemorrhage

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Sucralfate versus cimetidine in reflux esophagitis. A single-blind multicenter study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Cisapride versus placebo in reflux esophagitis. A multicenter double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Cimetidine 800 mg twice daily for healing erosions and ulcers in gastroesophageal reflux disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Comparative trial of pantoprazole and ranitidine in the treatment of reflux esophagitis. Results of a German multicenter study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IVa (a Dutch multicentre trial). Dutch Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Efficacy and tolerability of 20 mg pantoprazole versus 300 mg ranitidine in patients with mild reflux-oesophagitis: a randomized, double-blind, parallel, and multicentre study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Ranitidine 300 mg twice daily and 150 mg four-times daily are effective in healing erosive oesophagitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Acute treatment of reflux oesophagitis: a multicentre study to compare 150 mg ranitidine twice daily with 300 mg ranitidine at bedtime

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

A comparison of two doses of nizatidine versus placebo in the treatment of reflux oesophagitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Omeprazole is superior to ranitidine plus metoclopramide in the short-term treatment of erosive oesophagitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Cisapride in the treatment of gastro-oesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Two different dose regimens of cisapride in the treatment of reflux oesophagitis: a double-blind comparison with ranitidine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Cisapride and ranitidine in the treatment of gastro-oesophageal reflux disease--a comparative randomized double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Pantoprazole and omeprazole in the treatment of reflux oesophagitis: a European multicentre study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Cimetidine and metoclopramide in oesophageal reflux disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Double-blind crossover study of ranitidine and placebo in gastro-oesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Ranitidine, 150 mg three times a day, in the treatment of reflux oesophagitis. A placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Sucralfate versus cimetidine in reflux oesophagitis. A double-blind clinical study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Combination therapy of sucralfate and ranitidine, compared with sucralfate monotherapy, in patients with peptic reflux esophagitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

GERD pathogenesis, pathophysiology, and clinical manifestations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003244.PUB2

7 January 2021

Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: The U.S. multicenter study

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD003244.PUB2

Ranitidine for erosive oesophagitis: a double-blind, placebo-controlled study. Glaxo Erosive Esophagitis Study Group

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD003244.PUB2

Cimetidine in the treatment of reflux oesophagitis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD003244.PUB2

Sucralfate and alginate/antacid in reflux esophagitis

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1002/14651858.CD003244.PUB2

Identifiers

DOI

10.1002/14651858.CD003244.PUB2

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2620361

Fatcat ID

release_c3howpcf7fb2dfp5v5yv3jos34

0 references

OpenCitations bibliographic resource ID

2620361

1 reference